Cargando...
Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice
Intravitreal ranibizumab (IVR) has been approved for treating diabetic macular edema (DME), and is used in daily clinical practice. However, the treatment efficacies of IVR monotherapy in real-world clinical settings are not well known. The medical records of 56 eyes from 38 patients who received th...
Guardado en:
| Publicado en: | Medicine (Baltimore) |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wolters Kluwer Health
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5406051/ https://ncbi.nlm.nih.gov/pubmed/28422835 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000006459 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|